StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3053% above fair value
$30.00−0.67 (-2.18%)

Close on Nov 3, 2026Market cap $170.99BP/E 39.5Yield 5.73%

Pfizer Orgovyx (relugolix by Quarter

Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide revenues ($M) ($M)

Pfizer Orgovyx (relugolix: $146M in Q2 2026, up 50.5% from a year earlier. That is the highest of the 8 quarters on record here.

Latest, Q2 2026
146
Period ended Jun 28, 2026
Change on a year earlier
+50.5%
97 in Q2 2025
History
8 quarters
Since Q3 2024
Sources
4
Documents cited below

Where the Q2 2026 figure comes from

“|| Orgovyx (f) | 146 | 97 | 51% | 51% | 146 | 97 | 51% | — | — | — | —”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up orgovyx (relugolix

Cite this data

StockData. (2026). Pfizer Orgovyx (relugolix ($M), quarterly Q3 2024–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/orgovyx-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.

See a number that looks wrong?